Bionano Genomics (BNGO)
(Delayed Data from NSDQ)
$1.03 USD
+0.07 (7.80%)
Updated May 13, 2024 04:00 PM ET
After-Market: $1.03 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNGO 1.03 +0.07(7.80%)
Will BNGO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BNGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNGO
Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?
After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)
BNGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for
Will Bionano Genomics, Inc. (BNGO) Report Negative Q3 Earnings? What You Should Know
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
Other News for BNGO
Bionano Genomics price target lowered by $4.20 at Ladenburg, here's why
The 3 Best Healthcare Stocks to Buy in May 2024
Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
Bionano Genomics announces upgrades to cancer analysis suite
BioNano Genomics (BNGO) Gets a Buy from Scotiabank